Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Gains from Investment Securities: 2023-2025

Historic Gains from Investment Securities for Inhibrx Biosciences (INBX) over the last 2 years, with Sep 2025 value amounting to $19,000.

  • Inhibrx Biosciences' Gains from Investment Securities rose 157.58% to $19,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $116,000, marking a year-over-year decrease of 97.76%. This contributed to the annual value of $3.7 million for FY2024, which is 124.42% up from last year.
  • According to the latest figures from Q3 2025, Inhibrx Biosciences' Gains from Investment Securities is $19,000, which was up 216.67% from $6,000 recorded in Q2 2025.
  • Inhibrx Biosciences' 5-year Gains from Investment Securities high stood at $2.2 million for Q2 2024, and its period low was -$33,000 during Q3 2024.
  • Moreover, its 3-year median value for Gains from Investment Securities was $19,000 (2025), whereas its average is $588,889.
  • Per our database at Business Quant, Inhibrx Biosciences' Gains from Investment Securities tumbled by 3,200.00% in 2024 and then soared by 157.58% in 2025.
  • Over the past 3 years, Inhibrx Biosciences' Gains from Investment Securities (Quarterly) stood at $1.6 million in 2023, then slumped by 92.73% to $119,000 in 2024, then soared by 157.58% to $19,000 in 2025.
  • Its Gains from Investment Securities was $19,000 in Q3 2025, compared to $6,000 in Q2 2025 and -$28,000 in Q1 2025.